E/C/F/TAF + E/C/F/TAF (Low Dose)

Phase 2/3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Acquired Immune Deficiency Syndrome (AIDS)

Conditions

Acquired Immune Deficiency Syndrome (AIDS), HIV Infections

Trial Timeline

May 6, 2013 → Jun 18, 2025

NCT ID

NCT01854775

About E/C/F/TAF + E/C/F/TAF (Low Dose)

E/C/F/TAF + E/C/F/TAF (Low Dose) is a phase 2/3 stage product being developed by Gilead Sciences for Acquired Immune Deficiency Syndrome (AIDS). The current trial status is completed. This product is registered under clinical trial identifier NCT01854775. Target conditions include Acquired Immune Deficiency Syndrome (AIDS), HIV Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01854775	Phase 2/3	Completed	May 6, 2013	Jun 18, 2025	Acquired Immune Deficiency Syndrome (AIDS)

Competing Products

20 competing products in Acquired Immune Deficiency Syndrome (AIDS)

See all competitors

Product	Company	Stage	Hype Score
ONO-5046Na + ONO-5046Na	Ono Pharmaceutical	Phase 2	52
epoetin alfa	Johnson & Johnson	Phase 2	52
epoetin alfa	Johnson & Johnson	Phase 2	52
HRS-8427 + Meropenem	Jiangsu Hengrui Medicine	Phase 2	52
Ticagrelor + Placebo	AstraZeneca	Phase 2	52
IMI/REL FDC + PIP/TAZ FDC + Linezolid	Merck	Phase 3	77
Raltegravir + Atazanavir	Merck	Pre-clinical	23
Emicizumab Injection	Roche	Phase 2	52
PI + RTV + FTC/TDF + Stribild	Gilead Sciences	Phase 3	76
E/C/F/TDF + COBI + ATV + DRV + NRTI	Gilead Sciences	Phase 3	76
COBI + DRV + NRTIs	Gilead Sciences	Phase 3	76
Stribild	Gilead Sciences	Phase 3	76
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS	Gilead Sciences	Phase 2/3	64
D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF Placebo	Gilead Sciences	Phase 2	51
Lopinavir 400 mg/ritonavir 100 mg + Efavirenz	Gilead Sciences	Approved	84
E/C/F/TDF + ATV + RTV + FTC/TDF + E/C/F/TDF Placebo + ATV Placebo + RTV Placebo + FTC/TDF Placebo + E/C/F/TAF	Gilead Sciences	Phase 3	76
NNRTI + FTC/TDF + Stribild	Gilead Sciences	Phase 3	76
E/C/F/TDF + E/C/F/TAF Placebo + E/C/F/TAF + E/C/F/TDF Placebo	Gilead Sciences	Phase 2	51
EVG + Background regimen	Gilead Sciences	Phase 2/3	64
EVG/COBI/FTC/TDF	Gilead Sciences	Phase 2/3	64

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved